BLIS Technologies (NZSE:BLT) EBITDA: NZ$1.26 Mil (TTM As of Mar. 2026)


What is BLIS Technologies EBITDA?

BLIS Technologies NZSE:BLT EBITDA is NZ$1.26 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

BLIS Technologies's EBITDA for the six months ended in Mar. 2026 was NZ$0.58 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$1.26 Mil.

During the past 12 months, the average EBITDA Growth Rate of BLIS Technologies was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of BLIS Technologies was 72.00% per year. The lowest was -130.50% per year. And the median was 20.60% per year.

BLIS Technologies's EBITDA per Share for the six months ended in Mar. 2026 was NZ$0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of BLIS Technologies was 56.30% per year. The lowest was -58.70% per year. And the median was 30.70% per year.

BLIS Technologies  (NZSE:BLT) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


BLIS Technologies EBITDA Related Terms


BLIS Technologies EBITDA Historical Data

* Premium members only.

The historical data trend for BLIS Technologies's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLIS Technologies EBITDA Chart

BLIS Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.02 -0.75 1.26 1.49 1.26

BLIS Technologies Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.64 0.53 0.96 0.67 0.58

NZSE:BLT vs VRTX, REGN, ALNY: EBITDA Comparison

For the Biotechnology subindustry, BLIS Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BLIS Technologies's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

BLIS Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, BLIS Technologies's EBITDA was NZ$1.26 Mil.

BLIS Technologies's EBITDA for the quarter that ended in Mar. 2026 is calculated as

BLIS Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, BLIS Technologies's EBITDA was NZ$0.58 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$1.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of NZ$1.26 Mil mean?
BLIS Technologies (NZSE:BLT) has a EBITDA of NZ$1.26 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on BLIS Technologies.
Is BLIS Technologies' EBITDA too high?
BLIS Technologies' current EBITDA is NZ$1.26 Mil.
How does BLIS Technologies' EBITDA compare to VRTX and REGN?
BLIS Technologies' EBITDA of NZ$1.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on BLIS Technologies. BLIS Technologies's current EBITDA is NZ$1.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current EBITDA is NZ$1.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current EBITDA is NZ$1.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BLIS Technologies Business Description

Address 399 Moray Place, Dunedin Central, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.